Get the latest news, insights, and market updates on CSTL (Castle Biosciences, Inc.). Explore the news page 5 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Castle Biosciences (CSTL): Losses Narrow 9.6% Yearly, Profitability Challenges Weigh on Slow Revenue Growth
Castle Biosciences (CSTL) remains unprofitable but has reduced its losses at an average rate of 9.6% per year over the last five years. Revenue is projected to grow by 6.5% per year, notably slower than the US market average of 10.5%. The company’s current Price-To-Sales ratio of 2.7x is well above peers and the healthcare industry average. With a share price of $31.63 against an estimated fair value of $60.95, investors are left weighing narrowing losses and a discounted price against... Nov 5, 2025 - $CSTL
Recent Price Trend in Castle Biosciences (CSTL) is Your Friend, Here's Why
Castle Biosciences (CSTL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. Nov 5, 2025 - $CSTL
Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
Validation study data show AdvanceAD-Tx can identify patients with AD who have a ‘JAKi responder profile’ and a superior response to JAKi therapies compared to Th2-targeted therapiesFRIENDSWOOD, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the launch of AdvanceAD-Tx™, a gene expression profile (GEP) test designed to guide systemic treatment decision making in patients Nov 3, 2025 - $CSTL
Castle Biosciences Reports Third Quarter 2025 Results
Delivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 Q3 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 36% over Q3 2024 Raising full-year 2025 revenue guidance to $327-335 million from $310-320 million Announced launch of AdvanceAD-Tx™, the Company’s test designed to guide systemic treatment decision making in patients ages 12 and older with moderate-to-severe atopic dermatitis (AD) Conferenc Nov 3, 2025 - $CSTL
Castle Biosciences to Participate in Upcoming Investor Conferences
FRIENDSWOOD, Texas, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Stephens 27th Annual Investment Conference on Wednesday, Nov. 19, 2025, at 10:00 a.m. Eastern time. A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences Oct 28, 2025 - $CSTL
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple